Last reviewed · How we verify
Ferrlecit (sucroferric oxyhydroxide)
Ferrlecit binds to dietary phosphate in the gut, preventing its absorption into the bloodstream.
At a glance
| Generic name | sucroferric oxyhydroxide |
|---|---|
| Also known as | PA21 (Velphoro) |
| Sponsor | Vifor Fresenius |
| Drug class | Phosphate Binder [EPC] |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 2013 |
Mechanism of action
In the aqueous environment of the GI tract, phosphate binding takes place by ligand exchange between hydroxyl groups and/or water in sucroferric oxyhydroxide and the phosphate in the diet. The bound phosphate is eliminated with feces.Both serum phosphorus levels and calcium-phosphorus product levels are reduced as consequence of the reduced dietary phosphate absorption.
Approved indications
- Hyperphosphatemia
Common side effects
- Diarrhea
- Discolored feces
- Nausea
- Product taste abnormal
- Tooth discoloration
- Rash
Key clinical trials
- Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women (PHASE4)
- Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders (PHASE4)
- Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy (PHASE2,PHASE3)
- Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients (PHASE4)
- PA21 Safety and Efficacy in Adult Chinese Subjects (PHASE3)
- Velphoro and Impact on the Oral Cavity and Gut Microbiome
- Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)
- A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ferrlecit CI brief — competitive landscape report
- Ferrlecit updates RSS · CI watch RSS
- Vifor Fresenius portfolio CI